The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Open accessAbstract
Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates of mortality. Contingency management and psychotherapy interventions are the mainstays of treatment but are modestly effective with high relapse rates, while pharmacological treatments have shown little to no efficacy. Psilocybin-assisted psychotherapy is emerging as a promising treatment for a range of difficult-to-treat conditions, including substance use disorders; however, no studies have yet been published looking at psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Here we review the rationale for psilocybin-assisted psychotherapy as a potential treatment for this indication, and describe practical considerations based on our early experience designing and implementing four separate clinical trials of psilocybin-assisted psychotherapy for methamphetamine use disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the open-label design must be considered, this suggests 25 mg psilocybin may occasion a potent psychedelic effect in people with dependent MA use [17].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The putative transdiagnostic potential of psilocybin-assisted psychotherapy to enhance cognitive and neuronal plasticity, which are commonly impaired in substance use disorder, make it a promising novel treatment for MAUD [17].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Synaptic plasticity and addiction
Kauer, J. A., & Malenka, R. C. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2234 · Cited by 1,397 · cited 1×
“Drugs with high addiction potential, like methamphetamine, can hijack neuroplastic mechanisms in key brain regions, such as the mesolimbic dopamine system, ultimately contributing to the maladaptive maintenance of addictive behavior (50).”
BackgroundEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905 · cited 1×
“Lastly, psilocybin can occasion profound mystical-type experiences that mediate ratings of substantial personal meaning and spiritual significance (57, 60, 61).”
BackgroundBogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Research works printed but not linked: 2
- Dianne, 2021, S.854 - Methamphetamine response act of 2021.
- Hendricks, 2019, Psilocybin treatment of cocaine use disorder.
Cited by
Novel therapeutics in development for the treatment of stimulant-use disorder
Young, E. J., Radnai, L., Prikhodko, V., & Miller, C. A. (2024) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2024.102898 · Cited by 16
Sharma, P., Sawaya, M. F., Dumitrescu, A. M., Kolluru, G. K., Schmoutz, C. D., Salinas, A. G., Cannon, C. E., Kumbhare, D., Korneeva, N. L., Vest, M. F., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00770 · Cited by 15
Self-citationBrett, J., Knock, E., Watson, K., Albert, S., Siefried, K. J., & Guss, J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1490907 · Cited by 7
Self-citationKnock, E., Siefried, K. J., Bedi, G., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., & Brett, J. (2025) · Addiction · doi:10.1111/add.70187 · Cited by 9
Self-citationExploring the therapeutic potential of psychedelics in treating substance use disorders
Li, Y., Li, H., Wang, H., & Wang, X. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03168-w · Cited by 8
“Research needs to explore the potential of these compounds across different types of SUDs, including those with limited effective treatments, such as methamphetamine [79] and cocaine addiction.”
Metadata
- Authors
- Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., Patterson, J. C., & Stauffer, C. S.
- Affiliations
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- Oregon Health & Science University (US)
- Monash University (AU)
- Louisiana State University (US)
- University of Wisconsin–Madison (US)
- Corresponding author
- Stauffer, Christopher S.
- ORCID
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2023-03-14
- Volume
- 14
- Pages
- 1123424-1123424
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC10043240
- OpenAlex
- W4324145541
- Cited by
- 16
- References
- 87
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 2
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- psilocybin-assisted therapy, methamphetamine dependence, psychedelic therapy, addiction treatment, relapse, clinical trial design, treatment implementation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. https://app.cochat.ai/papers/10.3389/fpsyt.2023.1123424
- The paper
- Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., Patterson, J. C., & Stauffer, C. S. (2023). Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2023.1123424
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.